Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer

被引:181
作者
An, Hyun Joo
Miyamoto, Suzanne
Lancaster, Katherine S.
Kirmiz, Crystal
Li, Bensheng
Lam, Kit S.
Leiserowitz, Gary S.
Lebrilla, Carlito B. [1 ]
机构
[1] Univ Calif Davis, Dept Chem, Ctr Canc, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Internal Med, Div Hematol & Oncol, Ctr Canc, Davis, CA 95616 USA
[3] Univ Calif Davis, Div Gynecol Oncol, Dept Obstet & Gynecol, Davis, CA 95616 USA
关键词
ovarian cancer; biomarker; oligosaccharide; glycoprotein; MALDI; mass spectrometry;
D O I
10.1021/pr060010k
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A glycomic approach is developed to identify oligosaccharide markers for ovarian cancer by rapidly profiling globally released oligosaccharides. Glycoproteins shed by cancer cells are found in the supernatant (or conditioned media) of cultured cells. In this approach, shed glycoproteins are profiled for their oligosaccharide content using beta-elimination conditions. Changes in glycosylation are monitored by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR-MS). Because shed glycoproteins would also be found in serum, similar glycan profiling was performed to observe potential oligosaccharide markers. Oligosaccharide profiling data on a limited set of patient and normal serum samples were studied to determine potential glycan markers in ovarian cancer. We were able to demonstrate the presence of at least 15 unique serum glycan markers in all patients but absent in normal individuals. To determine the structure of the glycan biomarkers, a number of the ions were isolated and further analyzed using infrared multiphoton dissociation (IRMPD). One major advantage of this approach is that glycans are examined directly from patient sera without the need to obtain cancer biopsy specimens or to purify glycosylated proteins from these specimens.
引用
收藏
页码:1626 / 1635
页数:10
相关论文
共 30 条
  • [1] Determination of pathogen-related enzyme action by mass spectrometry analysis of pectin breakdown products of plant cell walls
    An, HJ
    Lurie, S
    Greve, LC
    Rosenquist, D
    Kirmiz, C
    Labavitch, JM
    Lebrilla, CB
    [J]. ANALYTICAL BIOCHEMISTRY, 2005, 338 (01) : 71 - 82
  • [2] Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-alpha-inhibitor
    Atmani, F
    Mizon, J
    Khan, SR
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 236 (03): : 984 - 990
  • [3] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
    BAST, RC
    KLUG, TL
    STJOHN, E
    JENISON, E
    NILOFF, JM
    LAZARUS, H
    BERKOWITZ, RS
    LEAVITT, T
    GRIFFITHS, CT
    PARKER, L
    ZURAWSKI, VR
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
  • [4] Pathways of O-glycan biosynthesis in cancer cells
    Brockhausen, I
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1999, 1473 (01): : 67 - 95
  • [5] The ProteinChip ® Biomarker System from Ciphergen Biosystems:: a novel proteomics platform for rapid biomarker discovery and validation
    Chapman, K
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 : 82 - 87
  • [6] Serum proteomics profiling - a young technology begins to mature
    Coombes, KR
    Morris, JRS
    Hu, JH
    Edmonson, SR
    Baggerly, KA
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (03) : 291 - 292
  • [7] Dabelsteen E, 1996, J PATHOL, V179, P358
  • [8] Biosynthesis of the cancer-related sialyl-α2,6-lactosaminyl epitope in colon cancer cell lines expressing β-galactoside α2,6-sialyltransferase under a constitutive promoter
    Dall'Olio, F
    Chiricolo, M
    Mariani, E
    Facchini, A
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (22): : 5876 - 5884
  • [9] Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO
  • [10] 2-5